{
  "offlabel-antrag.title": "Off-label application",
  "offlabel-antrag.description": "Capture an off-label application with core data and request details for insurer and doctor.",
  "offlabel-antrag.section.patient.title": "Patient",
  "offlabel-antrag.section.doctor.title": "Doctor",
  "offlabel-antrag.section.insurer.title": "Insurer",
  "offlabel-antrag.section.request.title": "Application",
  "offlabel-antrag.section.attachments.title": "Attachments",
  "offlabel-antrag.patient.firstName.label": "First name",
  "offlabel-antrag.patient.firstName.help": "Optional first name of the applicant",
  "offlabel-antrag.patient.lastName.label": "Last name",
  "offlabel-antrag.patient.lastName.help": "Optional last name of the applicant",
  "offlabel-antrag.patient.birthDate.label": "Birth date",
  "offlabel-antrag.patient.birthDate.help": "Optional birth date",
  "offlabel-antrag.patient.streetAndNumber.label": "Street and number",
  "offlabel-antrag.patient.streetAndNumber.help": "Optional street and number",
  "offlabel-antrag.patient.postalCode.label": "Postal code",
  "offlabel-antrag.patient.postalCode.help": "Optional postal code",
  "offlabel-antrag.patient.city.label": "City",
  "offlabel-antrag.patient.city.help": "Optional city",
  "offlabel-antrag.patient.insuranceNumber.label": "Insurance number",
  "offlabel-antrag.patient.insuranceNumber.help": "Optional health insurance number",
  "offlabel-antrag.doctor.name.label": "Name",
  "offlabel-antrag.doctor.name.help": "Optional doctor name",
  "offlabel-antrag.doctor.practice.label": "Practice",
  "offlabel-antrag.doctor.practice.help": "Optional practice name",
  "offlabel-antrag.doctor.streetAndNumber.label": "Street and number",
  "offlabel-antrag.doctor.streetAndNumber.help": "Optional practice street and number",
  "offlabel-antrag.doctor.postalCode.label": "Postal code",
  "offlabel-antrag.doctor.postalCode.help": "Optional practice postal code",
  "offlabel-antrag.doctor.city.label": "City",
  "offlabel-antrag.doctor.city.help": "Optional practice city",
  "offlabel-antrag.insurer.name.label": "Insurer name",
  "offlabel-antrag.insurer.name.help": "Optional insurer addressee",
  "offlabel-antrag.insurer.department.label": "Department",
  "offlabel-antrag.insurer.department.help": "Optional insurer department",
  "offlabel-antrag.insurer.streetAndNumber.label": "Street and number",
  "offlabel-antrag.insurer.streetAndNumber.help": "Optional insurer street and number",
  "offlabel-antrag.insurer.postalCode.label": "Postal code",
  "offlabel-antrag.insurer.postalCode.help": "Optional insurer postal code",
  "offlabel-antrag.insurer.city.label": "City",
  "offlabel-antrag.insurer.city.help": "Optional insurer city",
  "offlabel-antrag.request.drug.label": "Medication",
  "offlabel-antrag.request.drug.help": "Select the off-label medication",
  "offlabel-antrag.request.drug.option.agomelatin": "Agomelatine",
  "offlabel-antrag.request.drug.option.ivabradine": "Ivabradine",
  "offlabel-antrag.request.drug.option.vortioxetine": "Vortioxetine",
  "offlabel-antrag.request.standardOfCareTriedFreeText.label": "Standard care / alternatives already tried",
  "offlabel-antrag.request.standardOfCareTriedFreeText.help": "Which standard treatments were already used?",
  "offlabel-antrag.section.severity.title": "Severity and care level",
  "offlabel-antrag.section.severity.help": "These values are optional and included in the generated letter text.",
  "offlabel-antrag.severity.bellScore.label": "Bell score",
  "offlabel-antrag.severity.bellScore.help": "Select the documented Bell score.",
  "offlabel-antrag.severity.bellScore.option.10": "10",
  "offlabel-antrag.severity.bellScore.option.20": "20",
  "offlabel-antrag.severity.bellScore.option.30": "30",
  "offlabel-antrag.severity.bellScore.option.40": "40",
  "offlabel-antrag.severity.bellScore.option.50": "50",
  "offlabel-antrag.severity.bellScore.option.60": "60",
  "offlabel-antrag.severity.bellScore.option.70": "70",
  "offlabel-antrag.severity.bellScore.option.80": "80",
  "offlabel-antrag.severity.bellScore.option.90": "90",
  "offlabel-antrag.severity.bellScore.option.100": "100",
  "offlabel-antrag.severity.gdb.label": "Disability degree (GdB)",
  "offlabel-antrag.severity.gdb.help": "Select the documented disability degree.",
  "offlabel-antrag.severity.merkzeichen.label": "Special marker",
  "offlabel-antrag.severity.merkzeichen.help": "Optional marker linked to GdB (multi-select: G, aG, H, B).",
  "offlabel-antrag.severity.pflegegrad.label": "Care level",
  "offlabel-antrag.severity.pflegegrad.help": "Select the documented care level.",
  "offlabel-antrag.severity.workStatus.label": "Work status",
  "offlabel-antrag.severity.workStatus.help": "Select the matching work status.",
  "offlabel-antrag.severity.workStatus.option.au": "Unable to work",
  "offlabel-antrag.severity.workStatus.option.emRente": "Disability pension",
  "offlabel-antrag.severity.workStatus.option.berentet": "Retired",
  "offlabel-antrag.severity.workStatus.option.teilzeit": "Part-time capacity",
  "offlabel-antrag.severity.mobilityLevel.label": "Mobility level",
  "offlabel-antrag.severity.mobilityLevel.help": "Select the documented mobility level.",
  "offlabel-antrag.severity.mobilityLevel.option.housebound": "housebound",
  "offlabel-antrag.severity.mobilityLevel.option.bedbound": "bedbound",
  "offlabel-antrag.attachmentsFreeText.help": "One attachment per line, e.g. doctor letter, findings, lab results.",
  "offlabel-antrag.export.attachmentsHeading": "Attachments",
  "offlabel-antrag.export.sourcesHeading": "Sources",
  "offlabel-antrag.export.defaults.noSeverity": "No dedicated severity values are currently documented.",
  "offlabel-antrag.export.defaults.fallbackDiagnosisMain": "post-infectious ME/CFS / Long COVID",
  "offlabel-antrag.export.defaults.fallbackDiagnosisPots": "PoTS / orthostatic tachycardia",
  "offlabel-antrag.export.defaults.medicationSelectionHint": "Please select a medication from the list to include the medication-specific rationale block.",
  "offlabel-antrag.export.severity.bell": "My functional level is Bell score {{bellScore}}.",
  "offlabel-antrag.export.severity.gdb": "A disability degree (GdB) of {{gdb}} is documented{{marker}}.",
  "offlabel-antrag.export.severity.pflegegrad": "A nursing care level of {{pflegegrad}} is in place.",
  "offlabel-antrag.export.severity.workStatus": "My current work status is {{workStatus}}.",
  "offlabel-antrag.export.severity.mobility": "I am predominantly {{mobilityLevel}}.",
  "offlabel-antrag.export.part1.subject": "Application for case-by-case cost coverage (off-label use): {{drug}}",
  "offlabel-antrag.export.part1.p1": "I hereby request cost coverage for off-label prescription of {{medicationIngredient}} to treat {{diagnosisMain}}.",
  "offlabel-antrag.export.part1.p2": "The prerequisites for off-label coverage are met: this is a serious condition without a generally accepted standard therapy. There is a not-remote prospect of meaningful positive impact on disease course or symptom burden.",
  "offlabel-antrag.export.part1.p3": "For {{diagnosisMain}}, no causal standard therapy is currently available. Care is symptom-oriented and individualized.",
  "offlabel-antrag.export.part1.p4": "{{severitySummary}}",
  "offlabel-antrag.export.part1.p5": "In addition, I request cost coverage with explicit consideration of Section 2(1a) SGB V. In severe courses with no sufficiently effective standard options, individual coverage may be considered when there is a not-remote prospect of a meaningful positive impact on disease course. For classification of the ME/CFS care situation and application of Section 2(1a) SGB V, I refer to the decision of LSG Niedersachsen-Bremen dated 2022-10-14 (L 4 KR 373/22 B ER; attachment/source).",
  "offlabel-antrag.export.part1.p6": "Requested medication: {{medicationName}} ({{medicationIngredient}}).",
  "offlabel-antrag.export.part1.p7": "Treatment goal: {{targetSymptoms}} Dosing and duration: {{doseAndDuration}} Monitoring/stop criteria: {{monitoringAndStop}}",
  "offlabel-antrag.export.part1.p9": "I request a written decision within statutory deadlines. I am available for follow-up questions.",
  "offlabel-antrag.export.part1.p10": "Sincerely,",
  "offlabel-antrag.export.medication.agomelatin.p1": "In the assessment of the Expert Group Long COVID Off-Label Use at BfArM, agomelatine is described as an option for depressive symptoms and/or sleep disorders related to long/post-COVID.",
  "offlabel-antrag.export.medication.agomelatin.p2": "Planned dosing follows the expert-group assessment (e.g. 25 mg in the evening; escalation to 50 mg where clinically indicated).",
  "offlabel-antrag.export.medication.agomelatin.p3": "Monitoring: liver values according to product information/recommendations; review adverse effects and interactions.",
  "offlabel-antrag.export.medication.ivabradine.p1": "In the assessment of the Expert Group Long COVID Off-Label Use at BfArM, ivabradine is described as an option in post-infectious PoTS (long/post-COVID), especially when beta blockers are not tolerated or not suitable.",
  "offlabel-antrag.export.medication.ivabradine.p2": "Planned dosing follows the expert-group assessment: initial 2.5 mg in the morning; escalation in 2.5 mg steps up to 5 mg twice daily (with pulse control in supine and standing position).",
  "offlabel-antrag.export.medication.ivabradine.p3": "Monitoring: pulse/blood pressure, ECG where indicated; review interactions/contraindications. Pregnancy is contraindicated.",
  "offlabel-antrag.export.medication.vortioxetine.p1": "In the assessment of the Expert Group Long COVID Off-Label Use at BfArM, vortioxetine is described as an option for depressive symptoms and/or cognitive impairment related to long/post-COVID.",
  "offlabel-antrag.export.medication.vortioxetine.p2": "Planned dosing follows the expert-group assessment: initial 5 mg daily; increase to 10 mg daily after one week; maximum 20 mg daily. Evaluate effectiveness after about 12 weeks.",
  "offlabel-antrag.export.medication.vortioxetine.p3": "Note: clarify local availability/import where required. Monitoring: adverse effects/interactions and follow-up with symptom scoring.",
  "offlabel-antrag.export.part2.subject": "Cover letter regarding the off-label request (part 1) - request for support",
  "offlabel-antrag.export.part2.p1": "Dear Dr. {{doctorName}},",
  "offlabel-antrag.export.part2.p2": "I am preparing a cost-coverage request (part 1) to my insurer for an off-label prescription. I kindly ask for your support via a brief medical statement/findings summary (medical necessity, severity, prior measures, expected benefit, monitoring).",
  "offlabel-antrag.export.part2.supportBullets.b1": "- confirmed diagnoses and relevant findings",
  "offlabel-antrag.export.part2.supportBullets.b2": "- leading symptoms and treatment goal",
  "offlabel-antrag.export.part2.supportBullets.b3": "- prior treatment attempts and why no adequate standard option exists",
  "offlabel-antrag.export.part2.supportBullets.b4": "- planned dosing, monitoring, and benefit-risk assessment",
  "offlabel-antrag.export.part2.supportBullets.b5": "- where relevant, why waiting may lead to significant deterioration",
  "offlabel-antrag.export.part2.p3": "The technical basis is the assessment of the \"Expert Group Long COVID Off-Label Use at BfArM\" for the selected active ingredient (see sources/attachments).",
  "offlabel-antrag.export.part2.p4": "Important: Part 1 is my letter to the insurer and is not signed by you. Please provide a separate medical statement/findings summary as an attachment instead. A pre-formulated template (Part 3) is included and can be adapted by your practice.",
  "offlabel-antrag.export.part2.p5": "Summary: {{medicationName}} ({{medicationIngredient}}); treatment goal: {{targetSymptoms}} dosing/duration: {{doseAndDuration}} monitoring/stop: {{monitoringAndStop}}",
  "offlabel-antrag.export.part2.statement.heading": "DRAFT - Medical statement supporting an off-label request (please transfer to practice letterhead)",
  "offlabel-antrag.export.part2.statement.p1": "I, {{doctorName}}, confirm treatment of {{patientName}}, date of birth {{patientBirthDate}}. Diagnoses: {{diagnosisMain}} (ICD where available: {{diagnosisIcdList}}). Leading symptoms/exertion intolerance: {{targetSymptoms}}.",
  "offlabel-antrag.export.part2.statement.p2": "The disease burden is clinically relevant: {{severitySummary}} Functional capacity is clearly reduced (e.g. {{severityHighlights}}).",
  "offlabel-antrag.export.part2.statement.p3": "A causal, generally accepted standard therapy is currently not available for this clinical picture; care is mainly symptom-oriented. Prior measures/treatments (excerpt): {{priorTreatments}}. Relevant disease burden remains despite prior measures.",
  "offlabel-antrag.export.part2.statement.p4": "For symptomatic treatment, off-label therapy with {{drugName}} ({{drugSubstance}}) is requested, treatment goal: {{targetSymptoms}}. The indication rationale references the documentation of the Expert Group Long COVID Off-Label Use at BfArM.",
  "offlabel-antrag.export.part2.statement.p5": "Dosage proposal: {{doseText}} Treatment duration/trial: {{durationText}} Stop criteria: {{stopText}} Monitoring/safety: {{monitoringText}}",
  "offlabel-antrag.export.part2.statement.p6": "From a medical perspective there is a plausible prospect of meaningful positive impact on symptom burden. Alternative standard options are exhausted or unavailable in this individual case. Off-label prescribing is planned as a time-limited trial with defined stop criteria and monitoring.",
  "offlabel-antrag.export.part2.statement.p7": "{{dateLine}}",
  "offlabel-antrag.export.part2.statement.p8": "{{doctorName}}",
  "offlabel-antrag.export.statement.defaults.icdList": "—",
  "offlabel-antrag.export.statement.defaults.severityHighlights": "no additional severity markers documented",
  "offlabel-antrag.export.statement.severity.bell": "Bell score {{bellScore}}",
  "offlabel-antrag.export.statement.severity.gdb": "GdB {{gdb}}{{gdbSuffix}}",
  "offlabel-antrag.export.statement.severity.pflegegrad": "Care level {{pflegegrad}}",
  "offlabel-antrag.export.statement.severity.workStatus": "Work status {{workStatus}}",
  "offlabel-antrag.export.statement.severity.mobility": "Predominantly {{mobilityLevel}}",
  "offlabel-antrag.export.statement.medication.generic.doseText": "Please define dosage in the final medical statement.",
  "offlabel-antrag.export.statement.medication.generic.durationText": "Please define trial duration in the final medical statement.",
  "offlabel-antrag.export.statement.medication.generic.stopText": "Please define stop criteria in the final medical statement.",
  "offlabel-antrag.export.statement.medication.generic.monitoringText": "Please define monitoring and safety checks in the final medical statement.",
  "offlabel-antrag.export.statement.medication.agomelatin.doseText": "Standard dosage 25 mg in the evening; if no symptom improvement after 4 weeks, increase to 50 mg in the evening.",
  "offlabel-antrag.export.statement.medication.agomelatin.durationText": "Treatment duration between 2 weeks and 3 months (stop if no improvement); continue longer only when there is clear benefit.",
  "offlabel-antrag.export.statement.medication.agomelatin.stopText": "Stop treatment if transaminases exceed 3x upper normal limit and/or there are clinical signs of liver injury; stop during pregnancy.",
  "offlabel-antrag.export.statement.medication.agomelatin.monitoringText": "Liver function tests before start and during treatment according to product information; continuous benefit-risk review.",
  "offlabel-antrag.export.statement.medication.ivabradine.doseText": "Initial 2.5 mg twice daily; after 2 weeks increase to 5 mg twice daily if symptoms persist and resting pulse is >= 60/min.",
  "offlabel-antrag.export.statement.medication.ivabradine.durationText": "Treatment duration 4-12 weeks (symptom-oriented trial).",
  "offlabel-antrag.export.statement.medication.ivabradine.stopText": "Reduce dose or stop when resting pulse is < 50/min or bradycardia symptoms occur; stop when no pulse reduction and no clinical improvement are achieved.",
  "offlabel-antrag.export.statement.medication.ivabradine.monitoringText": "Monitor resting pulse and blood pressure; ECG monitoring as clinically required.",
  "offlabel-antrag.export.statement.medication.vortioxetine.doseText": "Initial 5 mg once daily; after 2 weeks increase to 10 mg once daily when response is insufficient; reduce back to 5 mg if not tolerated.",
  "offlabel-antrag.export.statement.medication.vortioxetine.durationText": "Treatment duration 4-12 weeks (trial).",
  "offlabel-antrag.export.statement.medication.vortioxetine.stopText": "Stop treatment when there is no clinical improvement or severe adverse effects occur (e.g. serotonin syndrome signs).",
  "offlabel-antrag.export.statement.medication.vortioxetine.monitoringText": "Clinical monitoring of adverse effects, tolerability and efficacy; consider interaction and serotonergic risk.",
  "offlabel-antrag.export.part2.attachmentsAutoItem": "Part 1: Insurer application (draft)",
  "offlabel-antrag.export.signatures.patientLabel": "Patient",
  "offlabel-antrag.export.signatures.doctorLabel": "Treating physician",
  "offlabel-antrag.export.sources.expert.agomelatin": "Assessment agomelatine – Expert Group Long COVID Off-Label-Use at BfArM (status 2025-12-02).",
  "offlabel-antrag.export.part2.p6": "Thank you for your support.\n\nSincerely,\n{{patientName}}",
  "offlabel-antrag.export.part3.title": "Part 3 – Template for medical statement / findings report (to be adapted by the practice)",
  "offlabel-antrag.export.part3.p1": "Patient: {{firstName}} {{lastName}}, DOB {{birthDate}}; insurance no.: {{insuranceNumber}}",
  "offlabel-antrag.export.part3.p2": "Diagnosis / suspected diagnosis: {{diagnosisMain}}",
  "offlabel-antrag.export.part3.p3": "Severity / functional impairment (short): {{severitySummary}}",
  "offlabel-antrag.export.part3.p4": "Prior treatment/care: no causal standard therapy available; treatment is symptom-oriented. Prior measures/medication (please add): ________________________________",
  "offlabel-antrag.export.part3.p5": "Rationale for off-label prescription: from a medical perspective, use of {{medicationIngredient}} for {{diagnosisMain}} is clinically plausible because the condition is severe, no standard therapy is available, and meaningful symptom improvement is plausible.",
  "offlabel-antrag.export.part3.p6": "Treatment plan (based on Expert Group evidence): treatment goal: {{targetSymptoms}} dosing/duration: {{doseAndDuration}}",
  "offlabel-antrag.export.part3.p7": "Monitoring/stop criteria (please adapt): {{monitoringAndStop}}",
  "offlabel-antrag.export.part3.p8": "Expected benefit / individual therapy goal (please add): ________________________________",
  "offlabel-antrag.export.part3.p9": "Date, stamp, signature: ________________________________",
  "offlabel-antrag.export.part3.p10": "{{medicationName}} ({{medicationIngredient}})",
  "offlabel-antrag.export.sources.mdBund": "Medical Service Federal Association: appraisal guidance / appraisal standards for off-label use (status 05/2022).",
  "offlabel-antrag.export.sources.caseLaw": "LSG Niedersachsen-Bremen: decision dated 2022-10-14, L 4 KR 373/22 B ER (ME/CFS; Section 2(1a) SGB V; missing standard therapy).",
  "offlabel-antrag.export.attachments.autoExpert.agomelatin": "Assessment: Agomelatine – Expert Group Long COVID Off-Label-Use at BfArM (status 2025-12-02)",
  "offlabel-antrag.export.part1.p8": "A medical statement on necessity and individualized rationale/prescribing is attached as a template. See cover letter to the treating practice (part 2) and template (part 3).",
  "offlabel-antrag.export.sources.expert.ivabradin": "Assessment ivabradine – Expert Group Long COVID Off-Label-Use at BfArM (status 2025-10-15).",
  "offlabel-antrag.export.sources.expert.vortioxetin": "Assessment vortioxetine – Expert Group Long COVID Off-Label-Use at BfArM (status 2025-10-15).",
  "offlabel-antrag.export.attachments.autoExpert.ivabradin": "Assessment: Ivabradine – Expert Group Long COVID Off-Label-Use at BfArM (status 2025-10-15)",
  "offlabel-antrag.export.attachments.autoExpert.vortioxetin": "Assessment: Vortioxetine – Expert Group Long COVID Off-Label-Use at BfArM (status 2025-10-15)",
  "offlabel-antrag.export.attachments.autoCaseLaw": "Case law: LSG Niedersachsen-Bremen, decision dated 2022-10-14, L 4 KR 373/22 B ER",
  "offlabel-antrag.ui.intro.title": "Notes",
  "offlabel-antrag.ui.intro.body": "Notes\n\nUsing this formpack is at your own risk. The content is a drafting aid and does not replace medical or legal advice.\n\nPlease review all entries carefully, align the final application with the treating practice, and only use accurate information.",
  "offlabel-antrag.ui.intro.checkboxLabel": "I understand, use at my own risk",
  "offlabel-antrag.ui.intro.startButtonLabel": "Continue",
  "offlabel-antrag.ui.intro.reopenButtonLabel": "Show notes",
  "offlabel-antrag.request.drug.option.other": "other medication or other indication",
  "offlabel-antrag.request.indicationFullyMetOrDoctorConfirms.label": "I fully meet the required diagnosis/indication or my doctor will confirm it",
  "offlabel-antrag.ui.infobox.p2a": "Select Yes if the diagnosis appears or should appear in a document. A matching confirmation sentence will be included in the medical report. If No, please select No. Chances of success are lower in that case. The doctor's letter will include a sentence confirming that symptoms of the respective indication are present.",
  "offlabel-antrag.request.applySection2Abs1a.label": "Also submit an auxiliary application under § 2 para. 1a SGB V",
  "offlabel-antrag.ui.infobox.section2a": "In some cases very narrowly defined diseases are selected, for example post-infectious ME/CFS. We aim for broad wording, but the medical service may disagree based on available data. If an application is rejected due to indication wording, an auxiliary application under § 2 para. 1a SGB V (hardship/emergency path) can be filed at the same time. Chances are significantly lower.",
  "offlabel-antrag.ui.infobox.drug.ivabradine": "Ivabradine: For patients who do not tolerate beta blockers or are not suitable for them.",
  "offlabel-antrag.ui.infobox.drug.agomelatine": "(Text pending)",
  "offlabel-antrag.ui.infobox.drug.vortioxetine": "(Text pending)",
  "offlabel-antrag.ui.infobox.drug.other": "For other medication or indication, the § 2 para. 1a SGB V hardship path applies with stricter requirements and lower chances of success. Add your own sources where possible and align risk-benefit reasoning with your treating doctor.",
  "offlabel-antrag.request.otherDrugName.label": "Name of other medication",
  "offlabel-antrag.request.otherDrugName.help": "Optional: active ingredient or product name.",
  "offlabel-antrag.request.otherIndication.label": "Other indication",
  "offlabel-antrag.request.otherIndication.help": "Optional: intended indication for the application.",
  "offlabel-antrag.severity.mobilityLevel.option.fullyBedbound": "completely bedbound"
}
